Steven Ruths, MD
Psychiatry · Ventura, CANPI 1093748519
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,418 of the $72,731 with a category attached, or 73.4%. AbbVie accounts for 81.0% of it on its own, with 26 other manufacturers making up the rest. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 590 payments — averaging $123.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$59K
- Sunovion Pharmaceuticals Inc.$5K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$985
- plus $5K from 21 others
What the payments were for
- Speaking & faculty fees$53,41873%
- Travel & lodging$2,3313%
- Food & beverage$16,75923%
- Education$2230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 319 | $58,908 |
| Sunovion Pharmaceuticals Inc. | 12 | $4,674 |
| Otsuka America Pharmaceutical, Inc. | 34 | $1,216 |
| Alkermes, Inc. | 22 | $1,100 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $1,015 |
| Teva Pharmaceuticals USA, Inc. | 20 | $985 |
| E.r. Squibb & Sons, L.L.C. | 12 | $755 |
| Vanda Pharmaceuticals Inc. | 27 | $539 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $456 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $434 |
| Neurocrine Biosciences, Inc. | 5 | $376 |
| Tris Pharma Inc | 5 | $285 |
| Almatica Pharma LLC | 15 | $281 |
| Axsome Therapeutics, Inc. | 8 | $267 |
| Indivior Inc. | 8 | $265 |
| Ironshore Pharmaceuticals Inc. | 7 | $236 |
| Johnson & Johnson | 3 | $184 |
| Idorsia Pharmaceuticals US Inc | 8 | $172 |
| Lundbeck LLC | 7 | $132 |
| Eisai Inc. | 1 | $115 |
| Boehringer Ingelheim | 1 | $92 |
| Bausch Health US, LLC | 4 | $63 |
| Supernus Pharmaceuticals, Inc. | 4 | $60 |
| Corium, LLC | 3 | $54 |
| Adlon Therapeutics L.p. | 2 | $30 |
| Orexo US, Inc. | 1 | $22 |
| Neos Therapeutics, LP | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$51,984
- LATUDA$4,437
- ARISTADA$1,985
- ARISTADA INITIO$496
- ABILIFY MAINTENA$482
- LYBALVI$453
- COBENFY$347
- Austedo XR$228
- CAPLYTA$226
- INGREZZA$225
- Dyanavel XR$219
- PERSERIS$125
- REXULTI$118
- Jornay PM 20mg capsules (Bottle of 100)$116
- Dayvigo$115
- AUSTEDO$110
- Auvelity$104
- INVEGA TRINZA$100
- INVEGA SUSTENNA$100
How this compares
$72,731 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 38 | $63,717 |
| Invega SustennaPaliperidone Palmitate | 23 | $54,865 |
| Aripiprazole | 159 | $23,743 |
| Lurasidone Hcl | 42 | $15,774 |
| VyvanseLisdexamfetamine Dimesylate | 21 | $11,689 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 65 | $11,118 |
| Chlorpromazine Hcl | 24 | $9,802 |
| Lisdexamfetamine Dimesylate | 17 | $8,143 |
| Clozapine | 43 | $6,179 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,292 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 25 | $3,988 |
| Bupropion XlBupropion Hcl | 130 | $3,050 |
| LoxapineLoxapine Succinate | 24 | $2,714 |
| Quetiapine Fumarate | 80 | $2,409 |
| Methylphenidate Hcl | 27 | $2,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $58,908 | $63,71738 claims |
| Johnson & JohnsonInvega Sustenna | $184 | $54,86523 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $456 | $16,98132 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $985 | $2,71424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Ventura
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.